GLP-1 Peptide Atlas, by Delfa

TerminatedPhase 1

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-07976016 AND PF-06882961 IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

Lead sponsor

Pfizer

Asset

Danuglipron

Oral · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI 25-40

Primary endpoints

•Steady state area under the concentration-time profile for PF-07976016•Steady state Cmax for PF-07976016•Steady state area under the concentration-time profile danuglipron

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06910839

Org study IDC5541009

Timeline

Milestones

Study start2025-03-13actual

Study first posted2025-04-04actual

Primary completion2025-05-01actual

Study completion2025-05-20actual

Last update posted2025-08-07actual

Assets

Investigational agents

Danuglipron

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Male and non-pregnant, non-breastfeeding female, 18 to 65 years of age

•BMI 25 to 40 kg/m2 and a total body weight > 50 kg (110 lb)

•Willing and able to comply with all study procedures including staying a research unit for up to 95 days

Exclusion criteria

•Any medical or psychiatric condition or laboratory abnormality, or recent serious illness or hospitalization, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study including diagnosis of type 2 diabetes mellitus, type 1 or secondary forms of diabetes

•Use of any prohibited prior or concomitant medication(s)

•Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests

•A positive urine drug test.

•History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence

•Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day or 2 chews of tobacco/day

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

5 endpoints

Primary/protocol endpoint

Steady state area under the concentration-time profile for PF-07976016

Time frame:From 0 Hours to 24 Hours following steady-state dose

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

Steady state maximum observed concentration (Cmax) for PF-07976016

Time frame:From 0 Hours to 24 Hours following steady-state dose

Cmax

concentration, descriptive

Primary/protocol endpoint

Steady state area under the concentration-time profile danuglipron

Time frame:From 0 Hours to 24 Hours following steady-state dose

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

Steady state maximum observed concentration (Cmax) for danuglipron

Time frame:From 0 Hours to 24 Hours following steady-state dose

Cmax

concentration, descriptive

Secondary/protocol endpoint

Number of participants with treatment emergent adverse events

Time frame:First dose (Day 1) through 28-35 days after final dose (approximately 18 weeks)

Treatment-emergent AEs (any)

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.